Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Houston Gene Therapeutics LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single outstanding matter is concentrated under the supervision of 1 distinct examiner, indicating a highly focused prosecution pipeline at this stage. The lack of diversity in examiners suggests that the company's current interactions with the USPTO are limited to a specific niche or a single active application.
The prosecution activity is further localized within 1 distinct art unit. This concentration means the portfolio's immediate legal challenges are confined to a single specialized group of reviewers. ALLISON MARIE JOHNSON serves as the busiest examiner for the company, currently handling 1 pending office action in her capacity as the primary reviewer. Because this examiner is responsible for the entirety of the company's pending workload, the outcome of this specific interaction will dictate the short-term success of the portfolio.
Practitioners should note that with only 1 pending office action, the portfolio does not currently face the complexities of multi-front prosecution. The focus on a single art unit and examiner allows for a highly targeted legal strategy. However, this also means the company's immediate patent prospects are entirely dependent on the findings of ALLISON MARIE JOHNSON.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996753 | Compositions for Treatment of Vascular Disease | JOHNSON, ALLISON MARIE | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996753 | Compositions for Treatment of Vascular Disease | JOHNSON, ALLISON MARIE | 1638 | §103 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHouston Gene Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Allison Marie Johnson has the most, with 1 of Houston Gene Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
